Fate Therapeutics
FATE
123 hedge funds and large institutions have $1.07B invested in Fate Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 42 increasing their positions, 45 reducing their positions, and 14 closing their positions.
40% more capital invested
Capital invested by funds: $762M → $1.07B (+$307M)
1.48% more ownership
Funds ownership: 92.1% → 93.59% (+1.5%)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
1% more funds holding
Funds holding: 122 → 123 (+1)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 45
31% less call options, than puts
Call options by funds: $4.55M | Put options by funds: $6.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$16.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$10.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.88M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.89M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$12.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.82M |
| 3 |
AG
Artal Group
Luxembourg
|
-$5.52M |
| 4 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$5.52M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.23M |
FATE Hedge Fund Activity: Q1 2019 in Review
123 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2019, worth a combined $1.07B — up 40% from $762M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FATE positions and 14 closed out — a net gain of 1 holder — while 42 added to existing stakes and 45 trimmed.
The largest buyer was Millennium Management, adding an estimated $16.1M. The largest seller was Arch Venture Management, cutting an estimated $12.6M.
- 123 institutional investors held Fate Therapeutics (FATE) as of Q1 2019, up from 122 in Q4 2018.
- Funds reported $1.07B of Fate Therapeutics stock for Q1 2019, up 40% quarter-over-quarter.
- 15 funds opened new Fate Therapeutics positions in Q1 2019 and 14 closed out, a net change of +1 holder.
- The largest Fate Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $16.1M added.
- The largest Fate Therapeutics seller in Q1 2019 was Arch Venture Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2019.